Brazil's Ministry of Health placed a $24 million order for Alfataliglicerase with Protalix BioTherapeutics Inc. to treat Gaucher patients in the country.

The company will deliver the drug in three shipments by the end of next year.

The order comes at a time when the company is pushing for Alfataliglicerase to become the preferred therapy for Brazilian Gaucher patients.